Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil

AIDS

Volumn 22, Issue 18, 2008, Pages 2527-2533

  Golub, Jonathan E ^a,b   Durovni, Betina ^c,d   King, Bonnie S ^a   Cavalacante, Solange C ^b,c   Pacheco, Antonio G ^c,d   Moulton, Lawrence H ^b   Moore, Richard D ^a,b   Chaisson, Richard E ^a,b   Saraceni, Valeria ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antiretroviral therapy; Brazil; HIV; Recurrence; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT;

ADULT; ANAMNESIS; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG USE; FEMALE; HEALTH CENTER; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT INFECTION; RISK ASSESSMENT; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; BRAZIL; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; RNA, VIRAL; TUBERCULIN TEST; TUBERCULOSIS; VIRAL LOAD;

EID: 57349100353     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328311ac4e     Document Type: Article

References (38)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-1021.
2. Mallory KF, Churchyard GJ, Kleinschmidt I, De Cock KM, Corbett EL. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2000;4:455-462.
3. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687-1693.
4. Johnson J, Kagal A, Bharadwaj R. Factors associated with drug resistance in pulmonary tuberculosis. iIndian J Chest Dis Allied Sci 2003;45:105-109.
5. Fujiwara PI, Cook SV, Rutherford CM, Crawford JT, Glickman SE, Kreiswirth BN, et al. A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med 1997;157:531-536.
6. Garcia-Garcia ML, Ponce de LA, Jimenez-Corona ME, Jimenez-Corona A, Palacios-Martinez M, Balandrano-Campos S, et al. Clinical consequences and transmissibility of drugresistant tuberculosis in southern Mexico. Arch Intern Med 2000;160:630-636.
7. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005;171:1430-1435.
8. van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-1179.
9. Panjabi R, Comstock GW, Colub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007;11:828-837.
10. Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 2001;33:1762-1769.
11. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-534.
12. Aber VR, Nunn AJ. Factors affecting relapse following shortcourse chemotherapy. Bull Int Union Tuberc 1978;53:260-264.
13. Pulido F, Pena JM, Rubio R, Moreno S, Gonzalez J, Guijarro C, et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997;157:227-232.
14. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV- infected patients in Rio de Janeiro, Brazil. AIDS 2007;21:1441-1448.
15. Moulton LH, GolubJE, Durovni B, Cavalcante SC, Pacheco AG, Saraceni V, et al. Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clin Trials 2007;4:190-199.
16. Castelo FilhoA, Kritski AL, Barreto AW, Lemos ACM, Netto AR, Gueimarares CA, et al. II Brazilian consensus on treatment of tuberculosis - Brazilian guidelines for tuberculosis 2004 [in Portuguese]. J Bras Pneumol 2004;30 (Suppl 2):S62-S64.
17. Selassie AW, Pozsik C, Wilson D, Ferguson PL. Why pulmonary tuberculosis recurs: a population-based epidemiological study. Ann Epidemiol 2005;15:519-525.
18. Kopanoff DE, Snider DE Jr, Johnson M. Recurrent tuberculosis: why do patients develop disease again? A United States Public Health Service cooperative survey. Am J Public Health 1988;78:30-33.
19. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV- associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis 2000;4:1026-1031.
20. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359:2059-2064.
21. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005;19:2109-2116.
22. Girardi E, Antonucci G, Vanacore P, Palmieri F, Matteelli A, lemoli E, et al. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. Eur Respir J 2004;24:11-17.
23. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Salten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
24. Grinsztejn B, Veloso VG, Pilotto JH, Campos DP, Keruly JC, Moore RD. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil. J Acquir Immune Defic Syndr 2007;45:515-520.
25. Lawn SD, Bekkar LG, Middlekoop K, Myer L, Wood R. Impact of HIV infection on the epidemiology of tuberculosis in a periurban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006;42:1040-1047.
26. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007;21:2483-2491.
27. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of posttreatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a radomised trial. Lancet 2000;356:1470-1474.
28. Churchyard GJ, Fielding K, Charalambous S, Day JH, Corbett EL, Hayes RJ, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS 2003;17:2063-2070.
29. Haller L, Sossouhounto R, Coulibaly IM, Dosso M, Kone M, Adorn H, et al. Isoniazid plus sulphadoxine-pyrimethamine can reduce morbidity of HIV-positive patients treated for tuberculosis in Africa: a controlled clinical trial. Chemotherapy 1999;45:452-465.
30. Cavalcante SC, Soares EC, Pacheco AG, Chaisson RE, Durovni B, DOTS Expansion Team. Community DOT for tuberculosis in a Brazilian favela: comparison with a clinic model. Int J Tuberc Lung Dis 2007;11:544-549.
31. Whalen CC, Johnson JL, Okwera A, Horn DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997;337:801- 808.
32. de Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV- infected patients in Brazil. AIDS 2001;15:2129-2135.
33. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-792.
34. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. iLancet 1993;342:268-272.
35. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-2457.
36. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000;283:1445-1450.
37. World Health Organization/Global Tuberculosis Programme and UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV [policy statement]. Wkly Epidemiol Rec 1999;74:385- 397.
38. World Health Organization. Interim policy on collaborative TB/HIV activities. WHO/HTM/TB/2004 330 2004.